3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Other neoplasm
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Squamous Intraepithelial Lesions
1
Papillomavirus Infections
1
HIV Infections
1
Anus Neoplasms
1
Acquired Immunodeficiency Syndrome
1
Interventions
Paclitaxel
153
Carboplatin
123
Bevacizumab
87
Cisplatin
66
pembrolizumab
58
Taxes
51
Gemcitabine
51
liposomal doxorubicin
39
Topotecan
37
olaparib
31
Immunoglobulin G
27
Disulfides
26
Cyclophosphamide
24
Brachytherapy
22
Docetaxel
21
human papillomavirus vaccine, L1 type 16, 18
20
niraparib
19
Platinum
19
Nivolumab
18
Magnetic Resonance Spectroscopy
18
1,2-diaminocyclohexaneplatinum II citrate
18
rucaparib
17
durvalumab
16
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
16
Doxorubicin
16
Radiotherapy, Intensity-Modulated
14
Radiation
13
Albumin-Bound Paclitaxel
13
fludarabine phosphate
12
fludarabine
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Laser Therapy
×
Gynecologic
×
Clear all
NCT02135419
2024-07-26
ANCHOR
AIDS Malignancy Consortium
Phase 3
Completed
4,446 enrolled
13 charts